Jaundice — Comprehensive Pathophysiology Notes

1. DEFINITION

The term "jaundice" derives from the French jaune (yellow). "Icterus" is used interchangeably in clinical settings. — Schwartz's Principles of Surgery, p. 1381

2. BILIRUBIN — NORMAL METABOLISM

2.1 Production

• ~80% of bilirubin is derived from the breakdown of hemoglobin in senescent red blood cells (RBC lifespan ~120 days) by the reticuloendothelial system (RES) — primarily in the spleen, liver, and bone marrow.
• The remaining 20% comes from:
  • Breakdown of other heme-containing proteins (myoglobin, cytochromes, catalase)
  • Ineffective erythropoiesis (premature destruction of RBC precursors in bone marrow)

1. Hemoglobin → Globin + Heme
2. Heme → Biliverdin (by heme oxygenase) — iron and CO are released
3. Biliverdin → Unconjugated bilirubin (indirect bilirubin) by biliverdin reductase

2.2 Transport in Blood

• Unconjugated bilirubin is water-insoluble and lipid-soluble
• Transported in blood tightly bound to albumin
• This binding prevents it from being filtered by the glomerulus (hence, unconjugated bilirubin does NOT appear in urine)

2.3 Hepatic Uptake

• At the hepatocyte sinusoidal membrane, bilirubin dissociates from albumin
• Taken up by carrier-mediated transport
• Intracellularly bound to ligandin (Y protein) and Z protein (prevent back-diffusion into plasma)

2.4 Conjugation

• In the smooth endoplasmic reticulum of hepatocytes
• Enzyme: UDP-glucuronosyltransferase (UGT1A1)
• Reaction: Unconjugated bilirubin + UDP-glucuronic acid → Conjugated bilirubin (bilirubin diglucuronide)
• Conjugated bilirubin is water-soluble, non-toxic, and direct-reacting in laboratory tests

2.5 Excretion into Bile

• Conjugated bilirubin is actively transported across the canalicular membrane into bile via the MRP2 (multidrug resistance-associated protein 2) transporter
• Excreted in bile into the duodenum

2.6 Intestinal Phase (Enterohepatic Circulation)

• In the intestine, bacterial enzymes convert bilirubin to urobilinogen
• Most urobilinogen is oxidized to stercobilin → gives stool its brown color
• A small portion is absorbed back (enterohepatic circulation) → enters portal blood → re-excreted by liver or filtered by kidneys → appears in urine as urobilin (contributes to yellow color of urine)

3. TYPES OF JAUNDICE

4. TYPE 1 — PREHEPATIC (HEMOLYTIC) JAUNDICE

4.1 Pathophysiology

• Bilirubin load exceeds the conjugating capacity of the liver
• Result: Unconjugated hyperbilirubinemia
• Unconjugated bilirubin is bound to albumin → cannot be filtered by kidneys → no bilirubinuria
• However, increased conjugation and excretion → more urobilinogen in gut → increased urobilinogenuria
• Increased stercobilin → dark/normal stools

Serum bilirubin in pure hemolytic jaundice rarely exceeds 5 mg/dL (the liver has sufficient reserve conjugating capacity); higher levels suggest hepatocellular co-disease. — Harrison's Principles of Internal Medicine, p. 366

4.2 Etiology

• Hereditary spherocytosis (spectrin defects)
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency
• Sickle cell disease (HbS)
• Thalassemia (α and β)
• Pyruvate kinase deficiency

• Immune-mediated (Coombs positive):
  • Autoimmune hemolytic anemia (warm/cold antibody types)
  • Hemolytic disease of the newborn (Rh/ABO incompatibility)
  • Drug-induced (methyldopa, penicillin)
  • Incompatible blood transfusion
• Non-immune-mediated (Coombs negative):
  • Microangiopathic hemolytic anemia (TTP, HUS, DIC)
  • Mechanical trauma (prosthetic heart valves — "waring blender effect")
  • Infections (malaria — Plasmodium species destroy RBCs; Clostridium)
  • Burns; toxins (snake venom, copper — Wilson disease)

• Megaloblastic anemia (B12/folate deficiency)
• Iron deficiency anemia
• Thalassemia (intramedullary destruction of erythroid precursors)
• Sideroblastic anemia

• Resorption of large hematomas (e.g., post-trauma)
• Massive blood transfusion (transfused RBCs have shortened survival)
• Infarcts with tissue breakdown

• Severe malnutrition, extensive burns → hypoalbuminemia → impaired transport of bilirubin to liver

4.3 Pathological Features

• Splenomegaly (hyperplasia of RES cells)
• Erythroid hyperplasia in bone marrow
• Pigment gallstones (bilirubin/calcium bilirubinate stones) — common complication
• Kernicterus (bilirubin encephalopathy) in neonates if unconjugated bilirubin is very high

5. TYPE 2 — HEPATIC (HEPATOCELLULAR / INTRAHEPATIC) JAUNDICE

5.1 Pathophysiology

1. Impaired uptake: Reduced hepatic uptake of bilirubin from blood (e.g., certain drugs, Gilbert syndrome)
2. Impaired conjugation: Deficiency or reduction of UGT1A1 enzyme activity (e.g., Gilbert, Crigler-Najjar, neonatal physiologic jaundice)
3. Impaired canalicular excretion: Conjugated bilirubin cannot be excreted into bile (Dubin-Johnson, Rotor syndrome)
4. Hepatocellular necrosis: Disruption of hepatocyte polarity and all steps of bilirubin metabolism
5. Intrahepatic cholestasis: Impaired bile flow within intrahepatic bile ductules despite no mechanical obstruction

Processes that interfere with excretion of bile lead to jaundice due to retention of bilirubin, and to cholestasis. — Robbins & Kumar Basic Pathology, p. 554

5.2 Etiology

• Viral hepatitis: HAV, HBV, HCV, HDV, HEV
  • In acute viral hepatitis: both conjugated and unconjugated bilirubin rise; initial rise in urobilinogen followed by its disappearance as hepatocyte function worsens
• Other viral infections: EBV (infectious mononucleosis), CMV, HSV
• Alcoholic hepatitis (Mallory body formation, neutrophilic infiltration, centrilobular necrosis)
• Non-alcoholic steatohepatitis (NASH/MASLD)

• Chronic hepatitis B, C
• Alcoholic cirrhosis
• NAFLD/NASH → cirrhosis
• Autoimmune hepatitis
• Wilson disease (hepatic copper accumulation → hepatocellular necrosis)
• Hemochromatosis (iron overload → fibrosis → cirrhosis)
• α1-Antitrypsin deficiency (misfolded protein accumulates in hepatocytes → ER stress → apoptosis)

• Predictable (dose-dependent): Acetaminophen (APAP) — toxic NAPQI metabolite causes centrilobular necrosis; carbon tetrachloride
• Idiosyncratic: Chlorpromazine (cholestasis), halothane (immune hepatitis), isoniazid (chronic hepatitis), oral contraceptives (cholestasis), anabolic steroids (cholestasis)
• Herbs, Amanita phalloides (death cap mushroom)

• Gilbert syndrome (most common hereditary hyperbilirubinemia): affects 4–7% of population; triggered by fasting, stress, illness, alcohol; benign, self-limited; unconjugated bilirubin typically < 3 mg/dL
• Crigler-Najjar: rare neonatal disease; Type I is fatal without liver transplant (the only definitive treatment); exchange transfusions and phototherapy are temporizing measures
• Dubin-Johnson: AR, MRP2 gene mutation; liver characteristically appears black/dark green due to melanin-like pigment accumulation; serum conjugated bilirubin elevated; benign prognosis

• Near-universal in newborns, peaks at day 2–4, resolves by day 10
• Mechanisms:
  • Fetal hemoglobin (HbF) has shorter RBC lifespan → increased bilirubin production
  • Immature UGT1A1 activity (low expression at birth)
  • Enhanced enterohepatic circulation (intestinal flora not yet established; β-glucuronidase deconjugates bilirubin in gut)
  • Reduced hepatic ligandin (Y protein) levels
• Benign if bilirubin < 12 mg/dL; pathologic if > 5 mg/dL on day 1 or rising rapidly
• Breast milk jaundice: mild unconjugated hyperbilirubinemia; hormonally mediated or related to increased enterohepatic resorption; usually resolves with continued breastfeeding

• Sepsis → reduced hepatic uptake and conjugation; intrahepatic cholestasis
• Total parenteral nutrition → cholestasis
• Congestive heart failure → centrilobular hepatic congestion → jaundice

• Hepatic metastases, lymphoma, granulomatous disease (sarcoidosis, TB), amyloidosis

5.3 Pathological Features

• Variable: ranging from hepatocyte swelling, steatosis, lobular inflammation, bridging necrosis, to fibrosis and cirrhosis
• Intracellular bile accumulation (cholestasis) visible on histology: bile casts (bile plugs) in canaliculi, feathery degeneration of hepatocytes, bile infarcts
• In conjugation defects: liver morphology may be normal (Gilbert) or show specific changes (Dubin-Johnson: dark pigment)

6. TYPE 3 — POSTHEPATIC (OBSTRUCTIVE / CHOLESTATIC) JAUNDICE

6.1 Pathophysiology

• Conjugated (direct) hyperbilirubinemia predominates
• Conjugated bilirubin is water-soluble → passes through glomerulus → bilirubinuria (dark urine — "coca-cola" or "tea-colored")
• No bilirubin reaches intestines → no urobilinogen → pale/clay-colored stools (acholic stools)
• Urobilinogen absent in urine
• Bile salts accumulate in skin → pruritus (intense itching)
• Impaired fat absorption and fat-soluble vitamins (A, D, E, K) → steatorrhea; vitamin K deficiency → prolonged prothrombin time; vitamin D deficiency → osteomalacia
• Prolonged obstruction → secondary biliary cirrhosis → portal hypertension

The two most common causes of posthepatic jaundice are gallstones within the bile duct and an obstructing tumor at the head of the pancreas. — Gray's Anatomy for Students

6.2 Etiology

• Most common cause of obstructive jaundice overall
• Secondary stones: formed in gallbladder, migrate to CBD
• Primary stones: form in bile duct (especially in Caroli disease, recurrent pyogenic cholangitis)
• Presents with Charcot's triad: RUQ pain, fever/chills, jaundice; if progresses → Reynolds pentad (Charcot + hypotension + mental confusion) = suppurative cholangitis (surgical emergency)

• Carcinoma of head of pancreas: most common malignant cause; typically presents with painless progressive jaundice + palpable gallbladder (Courvoisier's law — "painless jaundice + palpable gallbladder = malignancy not stones")
• Cholangiocarcinoma (bile duct cancer): Klatskin tumor (bifurcation), distal cholangiocarcinoma
• Periampullary carcinoma (ampulla of Vater)
• Gallbladder carcinoma extending to CBD
• Hepatocellular carcinoma invading bile ducts
• Metastatic disease to porta hepatis (lymph nodes compressing CBD) — from gastric, colonic, breast cancers

• Post-cholecystectomy bile duct injury
• Chronic pancreatitis (fibrotic stricture of distal CBD)
• Post-traumatic strictures
• Iatrogenic (post-ERCP)

• Autoimmune fibro-inflammatory disease of intra- and extrahepatic bile ducts
• Onion-skin fibrosis around bile ducts → "beaded" appearance on MRCP/ERCP
• Strong association with inflammatory bowel disease (especially ulcerative colitis — seen in ~80% of PSC)
• Leads to secondary biliary cirrhosis; increased risk of cholangiocarcinoma

• Neonatal; progressive obliteration of extrahepatic bile ducts
• Most common surgically correctable cause of conjugated neonatal hyperbilirubinemia
• Treatment: Kasai procedure (hepatic portoenterostomy); liver transplantation if Kasai fails

• Congenital dilatation of bile ducts; Type I most common
• Risk of cholangiocarcinoma

• Autoimmune destruction of small intrahepatic bile ducts
• Middle-aged women; anti-mitochondrial antibodies (AMA) in >95%
• Granulomatous bile duct destruction (florid duct lesion)
• Leads to intrahepatic cholestasis, fibrosis, cirrhosis
• Technically "intrahepatic cholestasis" but mechanism is obstructive

• Ascaris lumbricoides migrating into CBD
• Liver flukes (Clonorchis sinensis, Opisthorchis)
• Hydatid cyst compressing biliary tree

• Bile duct ligation
• Retained common duct stones
• Postoperative cholestasis (multifactorial)

6.3 Pathological Features

• Bile stasis in intrahepatic bile ducts (bile plugs in canaliculi and ducts)
• Feathery degeneration of hepatocytes (bile salt-mediated cell injury)
• Bile lakes (areas of necrosis filled with bile)
• Bile duct proliferation in portal tracts
• Periportal edema and fibrosis
• Chronic obstruction → secondary biliary cirrhosis
• Cholangitis: duct epithelium infiltrated by neutrophils

7. METABOLIC CHANGES IN JAUNDICE

7.1 Bilirubin Chemistry and Lab Tests

7.2 Metabolic Changes in Obstructive Jaundice

• Bile salts accumulate in plasma → pruritus, bradycardia, xanthomas (chronic)
• Fat malabsorption → steatorrhea, deficiency of fat-soluble vitamins:
  • Vitamin K deficiency → coagulopathy (PT prolonged; corrects with parenteral Vit K)
  • Vitamin D deficiency → hypocalcemia → osteomalacia
  • Vitamin A deficiency → night blindness
  • Vitamin E deficiency → peripheral neuropathy
• Hypercholesterolemia (impaired biliary cholesterol excretion) → xanthelasmas/xanthomas
• Alkaline phosphatase (ALP) elevated markedly (induced by bile salts in bile duct epithelium)
• GGT (gamma-glutamyl transferase) elevated (confirms hepatic origin of ALP)

7.3 Metabolic Changes in Hepatocellular Jaundice

• Aminotransferases (AST, ALT) markedly elevated → hepatocellular necrosis/inflammation
• Coagulopathy → reduced synthesis of clotting factors (II, V, VII, IX, X) by liver
• Hypoalbuminemia → reduced oncotic pressure → ascites, edema
• Hypoglycemia → impaired gluconeogenesis and glycogen storage
• Hyperammonemia → hepatic encephalopathy (impaired urea cycle)
• Impaired drug metabolism → prolonged drug half-lives

7.4 Metabolic Changes in Hemolytic Jaundice

• Anemia → pallor, fatigue, compensatory erythropoiesis
• Elevated LDH (released from lysed RBCs)
• Reduced haptoglobin (haptoglobin consumed binding free hemoglobin)
• Elevated reticulocyte count (bone marrow response)
• Hemoglobinuria (in severe intravascular hemolysis — hemosiderin in urine in chronic cases)
• Pigment (bilirubin) gallstones form due to chronic excess unconjugated bilirubin in bile

7.5 Bilirubin Toxicity

• Kernicterus (bilirubin encephalopathy): unconjugated bilirubin (unbound to albumin) crosses the blood-brain barrier (BBB)
  • Unconjugated bilirubin is lipid-soluble → deposits in basal ganglia, hippocampus, subthalamic nuclei (areas with high metabolic activity)
  • Inhibits neuronal mitochondrial respiration → cell death
  • Occurs in neonates when total bilirubin > 20–25 mg/dL (lower threshold in premature infants)
  • Clinical features: lethargy, hypotonia → opisthotonos, seizures → sensorineural hearing loss, choreoathetosis, intellectual disability
  • Note: conjugated bilirubin does NOT cause kernicterus (water-soluble, cannot cross BBB)

8. SPECIAL CLINICAL CONSIDERATIONS

8.1 Courvoisier's Law

8.2 Approach to Diagnosis

1. Is the hyperbilirubinemia isolated or accompanied by other liver enzyme abnormalities?
2. Is it predominantly conjugated or unconjugated?
3. Are the enzymes hepatocellular (↑ ALT/AST) or cholestatic (↑ ALP/GGT)?
4. Is the cholestasis intra- or extrahepatic (clinical + ultrasound)?

The serum bilirubin represents a balance between input from production and hepatic/biliary removal. Hyperbilirubinemia may result from overproduction, impaired uptake/conjugation/excretion, or regurgitation from damaged hepatocytes or bile ducts. — Harrison's Principles of Internal Medicine, p. 366

8.3 Diagnostic Flowchart (Simplified)

Elevated bilirubin
       |
  ┌────┴────┐
Unconjugated  Conjugated
(indirect ↑)  (direct ↑)
     |              |
Isolated?      Liver enzymes?
  Yes   No    ↑ALT/AST  ↑ALP/GGT
  |     |     (hepato-  (cholestatic)
Gilbert Hemolysis cellular)      |
Crigler-Najjar         |     Ultrasound for
Neonatal        Hepatitis  bile duct dilation
                Cirrhosis      |
                Drug      Dilated → ERCP/MRCP
                          Not dilated → PBC/PSC
                                        Drug/viral

9. SUMMARY TABLE — KEY DIFFERENTIATING FEATURES